Fredun Pharmaceuticals Ltd - 539730 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, please find herewith enclosed the Annual Secretarial Compliance Report of the Company for the year ended March 31, 2023, as issued by Ms. Kala Agarwal, Practicing Company Secretaries on May 25, 2023. Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance to Regulation 47(1) (b) of SEBI Listing Regulations, 2015; we enclose herewith the copies of the Newspaper cuttings of the Financials Results of the Company for the Quarter and Financial Year ended 31st March, 2023; as approved by the Board in its Meeting held on Wednesday, 24th May, 2023; published in the following newspapers on 26th May, 2023. A. Business Standard (English) B. Mumbai Lakshadeep (Marathi) Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Change in Management
Pursuant to Regu*ration 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby disclose the material events discussed and approved at the Board Meeting held on 24th May 2023, in pursuance to Schedule III of Listing Regulations: M/s. R.H Nisar & Co, (Chartered Accountant), has been appointed as Statutory Auditor of Fredun Pharmaceuticals Limited for the FY 2023-24. M/s. Joshi Apte & Associates., (Cost Accountant), has been re-appointed as Cost Auditor of Fredun Pharmaceuticals Limited for the FY 2023-24. M/s. Hiren P Shah & Associates., (Chartered Accountant), has been appointed as Internal Auditor of Fredun Pharmaceuticals Limited for the FY 2023-24. Fredun Pharmaceuticals Ltd - 539730 - Revised Results-Financial Results For F. Y. 31-03-2023
Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, May 24, 2023 at 04.00 p.m. has inter-alia, considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 2023 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. Enclosed are: a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Recommended Final Dividend at 7% per Equity Share having Face Value of Rs. 10/each for the Financial Year 2022-23; subject to the approval of the Shareholders at the ensuing 36th Annual General Meeting of the Company Fredun Pharmaceuticals Ltd - 539730 - Corporate Action-Board approves Dividend
Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, May 24, 2023 at 04.00 p.m. has inter-alia, considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 2023 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. Enclosed are: a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Recommended Final Dividend at 7% per Equity Share having Face Value of Rs. 10/each for the Financial Year 2022-23; subject to the approval of the Shareholders at the ensuing 36th Annual General Meeting of the Company Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Revised Outcome - Board Meeting Dated 24-05-2023
Revised outcome-Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, May 24, 2023 at 04.00 p.m. has inter-alia, considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 2023 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. Enclosed are: a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Recommended Final Dividend at 7% per Equity Share having Face Value of Rs. 10/- each for the Financial Year 2022-23; subject to the approval of the Shareholders at the ensuing 36th Annual General Meeting of the Company Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Fredun Pharmaceuticals announced Q4 & FY2023 results FY23 Revenues stood at Rs. 276 Cr, up by 22.29% YoY; Q4FY23 Revenues were up by 11.08% YoY to Rs 79.80 Cr. FY23 EBITDA grew to Rs. 29.58 Cr, an increase of 92% YoY; Q4FY23 EBITDA was higher by 127.50% YoY to Rs 12.24 Cr. Fredun Pharmaceuticals Ltd - 539730 - Result-Financial Results-31-03-2023
Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, May 24, 2023 at 04.00 p.m. has inter-alia, considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 2023 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. Enclosed are: a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Recommended Final Dividend at 7% per Equity Share having Face Value of Rs. 10/- each for the Financial Year 2022-23; subject to the approval of the Shareholders at the ensuing 36(tm) Annual General Meeting of the Company;s- Fredun Pharmaceuticals Ltd - 539730 - Corporate Action-Board approves Dividend
Pursuant to Regulation 30 and 33 of SEBI (LLODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, May 24, 2023 at 04.00 p.m. has inter-alia, considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 2023 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. Enclosed are: a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Recommended Final Dividend at 7% per Equity Share having Face Value of Rs. 10/- each for the Financial Year 2022-23; subject to the approval of the Shareholders at the ensuing 36(tm) Annual General Meeting of the Company; Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting
Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, May 24, 2023 at 04.00 p.m. has inter-alia, considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 2023 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. Enclosed are: a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Recommended Final Dividend at 7% per Equity Share having Face Value of Rs. 10/- each for the Financial Year 2022-23 subject to the approval of the Shareholders at the ensuing 36(tm) Annual General Meeting of the Company;